Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis

International Journal of Pediatric Endocrinology

Philippe F. Backeljauw¹  Nicole M. Sheanon² 

[1] Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA;Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave MLC 7012, Cincinnati 45229, OH, USA

关键词: Height;    Growth hormone;    Oxandrolone;    Turner syndrome;   

Others  :  1224840
DOI  :  10.1186/s13633-015-0013-3

 received in 2015-02-05, accepted in 2015-07-07,  发布年份 2015

【 摘 要 】

Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome effects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis young women with Turner Syndrome may not reach a normal height. Adjuvant therapy with oxandrolone is used but there is no consensus on the optimal timing of treatment, the duration of treatment and the long term adverse effects of treatment. The objective of this review and meta-analysis is to examine the effect of oxandrolone on adult height in growth hormone treated Turner syndrome patients. Eligible trials were identified by a literature search using the terms: Turner syndrome, oxandrolone. The search was limited to English language randomized-controlled trials after 1980. Twenty-six articles were reviewed and four were included in the meta-analysis. A random effects model was used to calculate an effect size and confidence interval. The pooled effect size of 2.0759 (95 % CI 0.0988 to 4.0529) indicates that oxandrolone has a positive effect on adult height in Turner syndrome when combined with growth hormone therapy. In conclusion, the addition of oxandrolone to growth hormone therapy for treatment of short stature in Turner syndrome improves adult height. Further studies are warranted to investigate if there is a subset of Turner syndrome patients that would benefit most from growth hormone plus oxandrolone therapy, and to determine the optimal timing and duration of such therapy.

【 授权许可】

   
2015 Sheanon and Backeljauw.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Rongen-Westerlaken C, Corel L, van den Broeck J, Massa G, Karlberg J, Albertsson-Wikland K et al.. Reference values for height, height velocity and weight in Turner’s syndrome. Swedish Study Group for GH treatment. Acta Paediatr. 1997; 86(9):937-42.
• [2]Rochiccioli P, David M, Malpuech G, Colle M, Limal JM, Battin J et al.. Study of final height in Turner’s syndrome: ethnic and genetic influences. Acta Paediatr. 1994; 83(3):305-8.
• [3]Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF et al.. Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr. 1998; 132(2):319-24.
• [4]Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ et al.. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose–response trial. J Clin Endocrinol Metab. 1999; 84(12):4607-12.
• [5]Naeraa RW, Nielsen J. Standards for growth and final height in Turner’s syndrome. Acta Paediatr Scand. 1990; 79(2):182-90.
• [6]Haeusler G, Schmitt K, Blumel P, Plochl E, Waldhor T, Frisch H. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner’s syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. J Clin Endocrinol Metab. 1996; 81(2):536-41.
• [7]Haeusler G, Frisch H, Schmitt K, Blumel P, Plochl E, Zachmann M et al.. Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. Eur J Pediatr. 1995; 154(6):437-44.
• [8]Rosenbloom AL, Frias JL. Oxandrolone for growth promotion in Turner syndrome. Am J Dis Child. 1973; 125(3):385-7.
• [9]Moore DC, Tattoni DS, Ruvalcaba RHA, Limbeck GA, Kelley VC. Studies of anabolic steroids .6. Effect of prolonged administration of oxandrolone on growth in children and adolescents with gonadal dysgenesis. J Pediatr. 1977; 90(3):462-6.
• [10]Joss E, Zuppinger K. Oxandrolone in girls with Turner’s syndrome. A pair-matched controlled study up to final height. Acta Paediatr Scand. 1984; 73(5):674-9.
• [11]Bareille P, Massarano AA, Stanhope R. Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. Eur J Pediatr. 1997; 156(5):358-62.
• [12]Rudman D, Goldsmith M, Kutner M, Blackston D. Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. J Pediatr. 1980; 96(1):132-5.
• [13]Zeger MP, Shah K, Kowal K, Cutler GB, Kushner H, Ross JL. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. Horm Res Paediatr. 2011; 75(1):38-46.
• [14]Sas TC, Gault EJ, Bardsley MZ, Menke LA, Freriks K, Perry RJ et al.. Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. Horm Res Paediatr. 2014; 81(5):289-97.
• [15]Menke LA, Sas TC, Stijnen T, Zandwijken GR, de Muinck Keizer-Schrama SM, Otten BJ et al.. Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. Horm Res Paediatr. 2011; 75(2):115-22.
• [16]Menke LA, Sas TC, van Koningsbrugge SH, de Ridder MA, Zandwijken GR, Boersma B et al.. The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome. J Voice. 2011; 25(5):602-10.
• [17]Menke LA, Sas TC, Visser M, Kreukels BP, Stijnen T, Zandwijken GR et al.. The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome. Horm Behav. 2010; 57(3):297-305.
• [18]Menke LA, Sas TC, Zandwijken GR, de Ridder MA, Stijnen T, de Muinck Keizer-Schrama SM et al.. The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome. Clin Endocrinol (Oxf). 2010; 73(2):212-9.
• [19]Nathwani NC, Hindmarsh PC, Massarano AA, Brook CG. Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids. Clin Endocrinol (Oxf). 1998; 49(1):107-13.
• [20]Querfeld U, Dopper S, Gradehand A, Kiencke P, Wahn F, Zeisel HJ. Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner’s syndrome. J Clin Endocrinol Metab. 1999; 84(3):967-70.
• [21]Ross JL, Mazzocco MM, Kushner H, Kowal K, Cutler GB, Roeltgen D. Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome. J Pediatr. 2009; 155(5):714-20.
• [22]Ross JL, Roeltgen D, Stefanatos GA, Feuillan P, Kushner H, Bondy C et al.. Androgen-responsive aspects of cognition in girls with Turner syndrome. J Clin Endocrinol Metab. 2003; 88(1):292-6.
• [23]Schmitt K, Hausler G, Blumel P, Plochl E, Waldhor T, Frisch H. The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich-Turner syndrome. Eur J Pediatr. 1997; 156(2):99-103.
• [24]Stahnke N, Stubbe P, Keller E. Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome. Horm Res. 1992; 37 Suppl 2:37-46.
• [25]Rosenfeld RG, Hintz RL, Johanson AJ, Sherman B, Brasel JA, Burstein S et al.. Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1988; 113(2):393-400.
• [26]Rosenfeld RG, Hintz RL, Johanson AJ, Sherman B. Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner’s syndrome. Acta Paediatr Scand Suppl. 1987; 331:59-69.
• [27]Rosenfeld RG, Hintz RL, Johanson AJ, Brasel JA, Burstein S, Chernausek SD et al.. Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial. J Pediatr. 1986; 109(6):936-43.
• [28]Rosenfeld RG, Frane J, Attie KM, Brasel JA, Burstein S, Cara JF et al.. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1992; 121(1):49-55.
• [29]Rosenfeld RG. Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results. J Endocrinol Invest. 1989; 12(8 Suppl 3):49-51.
• [30]Rosenfeld RG. Non-conventional growth hormone therapy in Turner syndrome: the United States experience. Horm Res. 1990; 33(2–4):137-40.
• [31]Job JC, Landier F. Three-year results of treatment with growth hormone, alone or associated with oxandrolone, in girls with Turner syndrome. The Kabi collaborative study group. Horm Res. 1991; 35(6):229-33.
• [32]Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenas L et al.. Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab. 1996; 81(2):635-40.
• [33]Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ et al.. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab. 2010; 95(3):1151-60.
• [34]Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC et al.. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: randomised, double blind, placebo controlled trial. BMJ. 2011; 342:d1980.
• [35]Stahnke N, Keller E, Landy H, Serono SG. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab. 2002; 15(2):129-38.